Presentation is loading. Please wait.

Presentation is loading. Please wait.

Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.

Published byGunnar Andersen Modified over 5 years ago

Similar presentations

Presentation on theme: "Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating."— Presentation transcript:

1 Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. PERSIST: An Open-Label Rollover Study to Evaluate the Safety and Efficacy of VX-770 in Cystic Fibrosis Patients; STRIVE: Evaluating the Efficacy and Safety of Treatment with VX-770 in CF patients with G551D Mutations; ENVISION: Evaluation of Efficacy and Safety of VX-770 in children six to eleven years old with CF; CFTR: cystic fibrosis transmembrane conductance regulator; FEV1: forced expiratory volume in 1 s; % pred: % predicted. Isabelle Sermet-Gaudelus Eur Respir Rev 2013;22:66-71 ©2013 by European Respiratory Society

Download ppt "Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating."

Similar presentations

Pulmonary response in sarcoidosis

Pulmonary response in sarcoidosis
Cardiovascular Impacts of High Frequency Chest Compression1

Cardiovascular Impacts of High Frequency Chest Compression1
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Bacterial contamination in the environment of hospitalised children with cystic fibrosis  Agnès Ferroni, Aurélie Werkhauser-Bertrand, Muriel Le Bourgeois,

Bacterial contamination in the environment of hospitalised children with cystic fibrosis  Agnès Ferroni, Aurélie Werkhauser-Bertrand, Muriel Le Bourgeois,
Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation  Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation  Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,
Advances in Cystic Fibrosis 2017

Advances in Cystic Fibrosis 2017
Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai 

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai 
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,
Cystic Fibrosis The Journal of Molecular Diagnostics

Cystic Fibrosis The Journal of Molecular Diagnostics
Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Advances in Cystic Fibrosis Perspectives From Orlando, 2016
Evaluating Effects of CFTR Modulation in Cystic Fibrosis

Evaluating Effects of CFTR Modulation in Cystic Fibrosis
Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)

Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)
Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Rescue of misfolded recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative Western blot obtained from HEK293 cells.

Rescue of misfolded recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative Western blot obtained from HEK293 cells.
Readthrough levels measured for the indicated cystic fibrosis transmembrane conductance regulator (CFTR) premature termination codon mutations, at basal.

Readthrough levels measured for the indicated cystic fibrosis transmembrane conductance regulator (CFTR) premature termination codon mutations, at basal.
High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy  Edith T. Zemanick, J. Kirk Harris,

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy  Edith T. Zemanick, J. Kirk Harris,
Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Similar presentations

Ads by Google